Modra’s oral formulation of docetaxel, ModraDoc006/r will bypass limitations associated with IV-delivered docetaxel and at the same time improve the bioavailability of the drug. ModraDoc006/r is currently in a Phase II study in patients with metastatic prostate cancer.
Docetaxel, a member of the taxane class of chemotherapeutics, is one of the most frequently applied anti-cancer drugs globally and is part of the standard treatment practices for several major cancer indications. Although part of docetaxel’s toxicity is related to its mode of action, a substantial level of toxicity is induced by the high initial docetaxel blood concentration after intravenous administration. Its excipients, polysorbate 80 and ethanol, are known to cause side effects. 


Phase I results with ModraDoc006/r published in the European Journal of Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more


Meet us at one of the following events:      
Read more